ERCC1和β-tubulinⅢ和TS及TOPOⅡα在浸润性乳腺癌组织中的表达及临床意义  

Expression and clinical significance of ERCC1 and β-tubulin Ⅲ and TS and TOPO Ⅱα in breast cancer

作　　者：孔鹏[1] 陈守华[1] 顾禾[1] 张丽丽[1] 

机构地区：[1]山东大学附属千佛山医院乳腺甲状腺外科,山东济南250014

出　　处：《中国现代普通外科进展》2014年第4期266-270,共5页Chinese Journal of Current Advances in General Surgery

基　　金：卫生部医药卫生科技发展中心课题(W2012FZ014)

摘　　要：目的:探讨核苷酸切除修复交叉互补基因1(ERCC1)、β-微管蛋白-Ⅲ(β-tubulinⅢ)、胸苷酸合成酶(TS)、拓扑异构酶Ⅱα(TOPOⅡα)在浸润性乳腺癌组织中的表达水平及临床意义。方法:用免疫组织化学法对53例乳腺癌患者肿瘤组织中的ERCC1、β-tubulinⅢ、TS、TOPOⅡα蛋白表达水平进行检测,并分析其与肿瘤大小、TNM分期、淋巴结转移、ER、PR表达水平的关系。结果:53例浸润性乳腺癌患者中ERCC1低表达率为75.47%(40/53),其表达与淋巴结阴性、ER阳性及PR阳性表达相关(P<0.05);β-tubulinⅢ低表达率为54.72%(29/53),其表达与年龄、肿瘤大小、肿瘤分期、淋巴结是否转移、ER及PR表达状态均无关(P>0.05);TS低表达率为83.02(44/53),其表达水平与肿瘤分期及ER阳性表达状态相关(P<0.05);TOPOⅡα高表达率为45.28%(24/53),其表达与肿瘤直径>2 cm、淋巴结阳性、ER阳性表达状态相关(P<0.05)。ERCC1、β-tubulinⅢ、TS、TOPOⅡα表达之间无相关性(P<0.05)。结论:ERCC1、β-tubulinⅢ、TS、TOPOⅡα在乳腺癌组织中的表达水平有助于判断浸润性乳腺癌患者对于化疗药物的敏感性,结合浸润性乳腺癌临床病理特征,为制定个体化化疗方案提供了重要理论依据。Objective： To detect the expression and clinical significance of ERCC1, β -tubulin III, TS, TOPO Ⅱ α in invasive breast cancer. Methods： ERCC1 ,TOPO Ⅱ α, β -tubulin III ,TS were tested by the patients with invasive breast cancer. And, the correlations between the expressions and clinicopathological features including tumor size, degree of infiltration, TNM stage, lymph node metastasis and ER, PR expression levels were analyzed. Results： Among 53 cases of breast cancer patients, the low expression rate of ERCC1 was 75.47%, and correlated with negative lymph node metastasis and positive ER and PR; the low expression of β -tubulin III was 54.71%, and had no related with all the clinicopathological features （P〉 0.05）; the low expression of TS was 79.24%, and correlated with TNM stage and positive of ER （P〈 0.05）; the high expression of TOPO Ⅱ α was 45.28%, and correlated with tumor size, positive lymph node and positive ER and PR. Conclusion： The expression levels of ERCC1, TOPO Ⅱ α, β-tubulin Ⅲ, TS in breast cancer is related with the sensitivity of chemotherapy drugs for breast cancer accurately, and provide an important theoretical basis for the individual chemotherapy.

关 键 词：乳腺肿瘤 ERCC1 拓扑异构酶Ⅱ α β-微管蛋白-Ⅲ TS 个体化治疗 

分 类 号：R737.9[医药卫生—肿瘤]